I would say that BUB spiked to a high of ~60c or so on hype relating to the FDA deal, much of which has evaporated once the realities of the USA IF market have sunk in (still highly a competitive monopoly in which it is expensive to do business).
In fact many A2M holders in this very forum were spruiking BUB during that period and painting A2M as hopeless for prioritising China. Having said that, I don't think BUB had much other choice than to go hard on the USA opportunity due to it's lack of China label registration. And by all accounts, its USA sales did somewhat stem the damage of its dismal China result.
A2M Price at posting:
$6.82 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)